During the past decade, ATP Clinical Research, Inc. conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 25 clinical trials were completed, i.e. on average, 64.1% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 19 clinical trials were completed. i.e. 146.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ATP Clinical Research, Inc." #1 sponsor was "ACADIA Pharmaceuticals Inc." with 5 trials, followed by "Naurex, Inc, an affiliate of Allergan plc" with 4 trials sponsored, "Novartis" with 4 trials sponsored, "Pfizer" with 4 trials sponsored and "Forest Laboratories" with 4 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ATP Clinical Research, Inc." #1 collaborator was "Pfizer" with 3 trials as a collaborator, "National Institute on Aging (NIA)" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "ATP Clinical Research, Inc." are "Alzheimer's Disease" (17 trials), "Alzheimer Disease" (10 trials), "Major Depressive Disorder" (8 trials), "Schizophrenia" (6 trials) and "Depressive Disorder, Major" (4 trials). Many other conditions were trialed in "ATP Clinical Research, Inc." in a lesser frequency.

Most popular intervention types in "ATP Clinical Research, Inc." are "Drug" (54 trials), "Other" (6 trials), "Biological" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Pimavanserin" (4 trials), "Rapastinel" (4 trials), "ATH-1017" (2 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "ATP Clinical Research, Inc." are 60 trials for "All" genders.

Currently, there are NaN active trials in "ATP Clinical Research, Inc.". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 35 completed trials in ATP Clinical Research, Inc., undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in ATP Clinical Research, Inc., 3 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 2 trials that are defined as “Not Applicable".